To establish in vitro and in silico models that predict clinical drug–drug interactions (DDIs) with the OATP1B1 (SLCO1B1) transporter.

Selection of oral bioavailability enhancing formulations during drug discovery
The objective of this paper was to identify oral bioavailability enhancing approaches for a poorly water-soluble research compound during drug discovery stages using minimal amounts of material.

SLP Subsidiary Words+ Launches EyePro GS™ System
In-house Design Widens Eye Gaze Offerings and Substantially Increases Margins

Pre-clinical and clinical pharmacokinetics of PF-02413873, a non-steroidal progesterone receptor antagonist
The recently discovered selective nonsteroidal progesterone receptor (PR) antagonist 4-[3-cyclopropyl-1-(methylsulfonylmethyl)-5-methyl-1H-pyrazol-4-yl]oxy-2,6-dimethylbenzonitrile (PF-02413873)...

Simulation of Tobramycin Pharmacokinetics After Topical Ophthalmic Administration
Tobramycin belongs to the class of aminoglycoside antibiotics. It does not bind to serum proteins [1], is eliminated mainly by renal secretion [2] and is poorly absorbed from the gastrointestinal tract [3].

Simulations Plus Reports Third Quarter FY2011 Financial Results and Announces Investor Conference Call
Record Quarterly Revenue of $3.44 Million; Consolidated Earnings Up 42% and EPS Up 49% from 3QFY10

The Application of Physiologically Based Pharmacokinetic Modelling to Understanding the Clinical Pharmacokinetics of UK-369,003
5-[2-Ethoxy-5-(4-ethyl-piperazine-1-sulfonyl)-pyridin-3-yl]-3-ethyl-2-(2-methoxy-ethyl)-2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one (UK-369,003) is a phosphodiesterase-5...

Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible
Danoprevir, a potent, selective inhibitor of HCV NS3/4A protease, has a short half-life in humans. Therefore, the feasibility of a controlled release (CR) formulation to allow less frequent dosing...

Optimism in a time of pessimism.
Back in 1974, Stewart Brand’s advice was to “stay hungry, stay foolish,” as a way of bringing a beginner’s mind to new challenges. He still follows that advice, and he now says, “The phrase allows you to open your mind and explore. It means putting aside the explanations provided by social constructs and ideologies.”

Semi-mechanistic PK/PD Model of the Effect of Odanacatib, a Cathepsin K Inhibitor, on Bone Turnover to Characterize Lumbar Spine and Distal Forearm Bone Mineral Density in a Phase IIb Study of Postmenopausal Women
Odanacatib (MK-0822), a potent, orally-active inhibitor of cathepsin K, is under clinical development for treatment of postmenopausal osteoporosis. This poster describes base model development of a…

Simulations Plus Reports Preliminary Revenues for Third Fiscal Quarter of FY2011
Growth Trend Continues with Another Record Quarter

Innovation at the intersection of creativity and automation
Chapter 3 of 3. Need to catch up? Read the previous post in this series about scientific workflows.
In the same way that the guillotine concentrates the senses, the need to improve productivity in the pharmaceutical industry has become a life-or-death imperative. Improving productivity does not mean working harder and faster while doing the same job as before. Improving productivity lies in innovation—in the technology and processes that clever minds bring into existence. Moreover, what this innovation must accomplish is vividly clear. We must reduce the time and cost of drug development; increase the probability of successful experiments; and bring better drugs to the marketplace.

Simulating the Disposition of Triamcinolone Acetonide following Oral and Pulmonary Administration
Absorption, distribution and clearance of triamcinolone acetonide (TA) from oral and pulmonary administrations have been simulated using GastroPlus™,1. Simulation of orally administered doses and swallowed…

Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling
The importance of predicting human pharmacokinetics during compound selection has been recognized in the pharmaceutical industry. To this end there are many different approaches that are applied.

Why don’t computer systems help me as much as I think they should?
Answer: We don’t really understand the requirements of the process.
Chapter 2 of 3. Need to catch up? Read the previous post in this series about scientific workflows.

A Model of Threshold Behavior Reveals Rescue Mechanisms of Bystander Proteins in Conformational Diseases
Conformational diseases result from the failure of a specific protein to fold into its correct functional state. The misfolded proteins can lead to the toxic aggregation of proteins.

Scientific workflows – the knowledge-generating engines of R&D.
Scientific research requires two kinds of effort. One is the generation and synthesis of original ideas by skilled practitioners. This is a desirable and often lauded talent that can spawn remarkable innovations in science and medical care. The second kind of effort is less visible, but equally important—the hard work required to turn an idea into reality. Executing the experiments, analyzing the data, and developing presentations of results are examples of this work. Although these latter efforts are necessary, and even enjoyable, they nonetheless can be tedious, time-consuming, and expensive.

Simulations Plus Sets Date for 2nd Quarter 2011 Earnings Release and Conference Call
Conference Call to Be on Monday, April 18, at 4:15 PM EDT

Simulations Plus (SLP) Releases MedChem Studio 2.0
Adds New MedChem Designer Molecule Drawing, Expanded Graphics, and More

Mixture Modeling as a Data Imputation Method
To demonstrate the use of mixture modeling in population PK analysis to predict drug concentrations for a subset of subjects with missing data for a key categorical covariate.